After a fourth quarter in which revenue boomed throughout the biopharma industry, there were reversals for several drugmakers ...

Eli Lilly and Company and SiteOne Therapeutics, Inc. ("SiteOne"), a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal ...

The supply of GLP-1 drugs has been increasing, but they’re still expensive for most patients. Here are answers to some ...

"We are introducing Wegovy (injectable Semaglutide 2.4 mg) this year, which offers full therapeutic strengths of semaglutide ...

Despite Lars Fruergaard Jørgensen's resignation as Novo Nordisk's CEO, its stock price has risen 10% over the past two weeks.

The Danish company’s controlling shareholder, the Novo Nordisk Foundation, had pushed him to step down after the share price ...

That is the kind of half-joking question that doctors kick around when a new class of drugs begins to help a big chunk of the ...

Health insurance plans are changing how they cover GLP-1 drugs for weight loss to rein in costs, forcing doctors and patients ...

If you are looking to get a weight loss drug but lack insurance coverage, telehealth websites such as Ro, Hers and Mochi Health sell GLP-1 drugs for lower prices than what you’d pay at a pharmacy, ...

Goldman Sachs lowered its forecast for the total market for anti-obesity drugs through the end of the decade. Asad Haider, ...

Tirzepatide, the newest weight loss drug in India, is transforming the wellness market with its hormone-mimicking effects.

With political action underway through an executive order from President Donald Trump and pharmaceutical industry shifts emerging, the question remains whether these changes will lead to sustained ...